Generer rapport
Algiecel Aps
Helgavej 26, 5230 Odense M, CVR 42394416
Virksomhedsform
Anpartsselskab
Etableret
2021
Størrelse
Mikro
Ansatte
4
Omsætning
-
DKK
Bruttofortj.
-6.188.973
DKK
Primært resultat (EBIT)
-
DKK
Årets resultat
-6.697.004
DKK
Egenkapital
-1.379.532
DKK
Reklamebeskyttet virksomhed
Denne virksomhed er reklamebeskyttet. Det betyder bl.a. at oplysningerne ikke må bruges til reklamehenvendelser. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
305/359
"Bund 35%"
Rang i Danmark
337.959/344.048
"Bund 10%"
Direktion top 3
| Henrik Busch-Larsen 8 | Direktør |
Bestyrelse top 3
| Tina Moe 8 | Bestyrelsesformand |
| Henrik Busch-Larsen 8 | Bestyrelsesmedlem |
| Jeppe Høier 2 | Bestyrelsesmedlem |
Legale ejere top 3
| 66.67-89.99% | Hbl Invest Aps | DK |
| 10-14.99% | Aurelius Limited | GB |
| 5-9.99% | Manila Invest Aps | DK |
Tegningsregler
Selskabet tegnes af en direktør, af en direktør og bestyrelsesformanden i forening, eller af den samlede bestyrelse.
Stamoplysninger baseret på CVR
| Navn | Algiecel Aps |
| CVR | 42394416 |
| Adresse | Helgavej 26, 5230 Odense M |
| Branche | Forskning og eksperimentel udvikling indenfor bioteknologi [721100] |
| Web | www.algiecel.com |
| Etableret | 17-05-2021 (2 år) |
| Første regnskabsperiode | 17-05-2021 til 31-12-2021 |
| Virksomhedsform | Anpartsselskab |
| Antal ansatte | 17 (årsværk:12) |
| Reklamebeskyttelse | Ja |
| Revisor | Beierholm, Statsautoriseret Revisionspartnerselskab siden 17-05-2021 |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 1.011.946 DKK 961.946 DKK (26-06-2023 - 21-03-2024) 902.246 DKK (03-04-2023 - 25-06-2023) 845.484 DKK (27-10-2022 - 02-04-2023) 725.000 DKK (21-02-2022 - 26-10-2022) 712.500 DKK (30-07-2021 - 20-02-2022) |
| Vedtægter seneste | 22-03-2024 |
Medlem af brancherne
- Forskning og eksperimentel udvikling indenfor bioteknologiNACE6 indeholdende 556 virk.
- Forskning og eksperimentel udvikling indenfor naturvidenskab og teknikNACE3 indeholdende 1.770 virk.
- Videnskabelig forskning og udviklingNACE2 indeholdende 2.062 virk.
- Liberale, videnskabelige og tekniske tjenesteydelserNACE1 indeholdende 86.844 virk.
Formål
Selskabets formål er forskning, udvikling, produktion, fabrikation, handel og andet i forbindelse hermed beslægtet virksomhed efter selskabets skøn.
Regnskab
| 2022 | 2021 | |
|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK |
| Omsætning | - - | - - |
| Bruttofortjeneste | -6.189 - | -1.331 - |
| Årets resultat | -6.697 - | -1.283 - |
| Egenkapital | -1.380 - | 217 - |
| Balance | 5.645 - | 1.484 - |
Ledelsesberetning
Development in activities and financial affairs
The income statement for the period 01.01.22 - 31.12.22 shows a profit/loss of DKK -6,697,004 against DKK -1,282,614 for the period 17.05.21 - 31.12.21. The balance sheet shows equity of DKK -1,379,532.
In the beginning of 2022, ALGIECEL got accepted into the BioInnovation Institute’s Venture Lab programme, which also included a convertible loan note of DKK 4,000,000. Important milestones were achieved during 2022 where ALGIECEL finalized the design and construction of its pilot photobioreactor plant, and a collaboration agreement with Danish Technical Institute (TI) was signed. The pilot photobioreactor plant is in operation at TI’s premises in Taastrup, Denmark, where it has yielded strong initial results, seeing a major productivity increase from the initial test run in Q3 2022 to the start of 2023.
Additionally, during 2022 European Union React grant and Innobooster grant funding totalling approximately DKK 3,000,000 has been obtained for the basic design of the first full-scale demonstration unit and pilot lab-scale downstream processing and shelf-life testing, respectively. On the commercial side, interest in the technology and the opportunity has been positive, demonstrated by letters of interest signed by potential technology clients and by potential buyers of the algae-based derivative products.
Looking into 2023 ALGIECEL will work towards i) optimization of the algae-based carbon capture and utilization (CCU) technology; ii) initiating product application trials with potential clients and research institutes already identified to further the commercial interest in the high-value biomass products; iii) creating additional commercial interest from potential future clients in the CCU technology as well as iv) completing the design of the first full-scale demonstration unit. Moreover, ALGIECEL will work on securing additional funding for the upcoming demonstration full-scale project which will be key to the future development of ALGIECEL and the technology.
The income statement for the period 01.01.22 - 31.12.22 shows a profit/loss of DKK -6,697,004 against DKK -1,282,614 for the period 17.05.21 - 31.12.21. The balance sheet shows equity of DKK -1,379,532.
In the beginning of 2022, ALGIECEL got accepted into the BioInnovation Institute’s Venture Lab programme, which also included a convertible loan note of DKK 4,000,000. Important milestones were achieved during 2022 where ALGIECEL finalized the design and construction of its pilot photobioreactor plant, and a collaboration agreement with Danish Technical Institute (TI) was signed. The pilot photobioreactor plant is in operation at TI’s premises in Taastrup, Denmark, where it has yielded strong initial results, seeing a major productivity increase from the initial test run in Q3 2022 to the start of 2023.
Additionally, during 2022 European Union React grant and Innobooster grant funding totalling approximately DKK 3,000,000 has been obtained for the basic design of the first full-scale demonstration unit and pilot lab-scale downstream processing and shelf-life testing, respectively. On the commercial side, interest in the technology and the opportunity has been positive, demonstrated by letters of interest signed by potential technology clients and by potential buyers of the algae-based derivative products.
Looking into 2023 ALGIECEL will work towards i) optimization of the algae-based carbon capture and utilization (CCU) technology; ii) initiating product application trials with potential clients and research institutes already identified to further the commercial interest in the high-value biomass products; iii) creating additional commercial interest from potential future clients in the CCU technology as well as iv) completing the design of the first full-scale demonstration unit. Moreover, ALGIECEL will work on securing additional funding for the upcoming demonstration full-scale project which will be key to the future development of ALGIECEL and the technology.
02-05-2023